Boehringer Ingelheim acquires GST to expand stem cell capabilities

By Nikita Chaurasia  Date: 2020-07-29

Boehringer Ingelheim acquires GST to expand stem cell capabilities

Boehringer Ingelheim, a leader in pharmaceutical products, has recently made it to the headlines by acquiring Belgium-based veterinary biotech firm, Global Stem cell Technology (GST).

According to reliable sources, the collaboration with GST will allow Boehringer to expand its development pipeline, while parallelly focusing on setting higher standards of animal healthcare. However, the financial details of the deal were not disclosed.

The two companies had initially partnered in the year 2018 and had launched a stem cell product, Arti-Cell® Forte in 2019.  Arti-Cell® Forte is apparently the first stem cell product which was granted marketing authorization by the European commission in the veterinary domain.

Boehringer Ingelheim Animal Health’s Head of Global Strategic Marketing Jean-Luc Michel, was reported stating that the company had finally decided to acquire GST after two years of partnership which will help in expanding Boehringer Ingelheim’s portfolio. He added that GST’s expertise in stem cell production will allow Boehringer to  deliver advanced and innovative solutions to their clients.

Jan Spaas CEO of GST mentioned that that Boehringer Ingelheim’s mission to lead a new wave of development and innovation in the veterinary industry complies with GST vision. He further claimed that GST will operate as a new research and development division Boehringer’s banner.

For those uninitiated, Boehringer Ingelheim Animal Health is one of the largest animal health businesses in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries.

On the other hand, Global Stem cell Technology (GST) is a biotech company with primary focus on R&D activities and manufacture of veterinary stem cell-based products.

In other news, Boehringer Ingelheim had recently teamed up with Biognosys to enhance next-gen proteomics applications for drug development and discovery.

Source credits: https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-global-stem-cell-technology

https://www.news-medical.net/news/20200724/Boehringer-Ingelheim-and-Biognosys-join-forces-on-applying-quantitative-proteomics-tools-in-drug-discovery.aspx

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

U.K. might ease lockdown restrictions following drop in COVID-19 cases

U.K. might ease lockdown restrictions following drop in COVID-19 cases

By Nikita Chaurasia

British Prime Minister Boris Johnson is reportedly planning to further ease lockdown restrictions in the United Kingdom. This announcement comes after Britain witnessed a drop in the daily death toll and case count, primarily due to rapid vaccination...

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

By Nikita Chaurasia

Maruti Suzuki India Limited has reportedly extended its maintenance shutdown from May 9th to May 16th amidst rising COVID-19 cases across the country. However, it is difficult to ascertain whether the intention behind the extended shutdown is to guar...

Amazon sets tougher rules for its delivery service partners’ employees

Amazon sets tougher rules for its delivery service partners’ employees

By Nikita Chaurasia

Amazon is known for closely managing its staff and contractors, and it also seeks to control the employees of the companies in which it works. Reportedly, the company has updated its policies for Amazon’s delivery partners wherein it lays out d...

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

By Nikita Chaurasia

Solid Power Inc., a leading U.S-based producer of solid-state batteries has reportedly secured USD 130 million in the Series B funding round led by renowned car makers namely Ford Motor Company and BMW Group.  These funds will be used to develo...

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

By Nikita Chaurasia

Reportedly, American multinational pharmaceutical firm Pfizer Inc. has extended a helping hand to India in the battle against Covid-19, sending drugs worth USD 70 million to the country. The company is also in discussion with the Indian government to...